

10/530779

PTO/SB/08B (08-03)

App. for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		Complete if Known Application Number 1013 REG U PCT/PTO	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Filing Date	
		First Named Inventor	DUDICH Elena
		Art Unit	
		Examiner Name	
		Attorney Docket Number	Caspase
Sheet		of	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BENNET et al. 2001: A petide derived from alpha fetoprotein prevents... PNAS vol 99; no4. 2211-2215	
		DUDICH I. et al 1999. Isolation and Structural and Functional Characterization.. Biochemistry 38:10406-10414	
		BUCKLEY et al. 1999. RGD peptides induce apoptosis by direct caspase.. Nature vol 397 p. 534-539	
		BRATTON S. B et al. 2001. Recruitment, activation and retention of ... The EMBO Journal 20. no 5. pp 998-1009	
		COHEN G. M. 1997. Caspase: the executionres of apoptosis. Biochem J. 326: 1-16	
		DUDICH E. et al. 1999 Alpha Fetprotein causes apoptosis in tumor... Eur. J. Biochem. 266, 750-761	
		SEMENKOVA L. et al. 2003. Alpha Fetoproein positively regulates cytochrome Eur. J. Biochem 270: 4388-4399.	
		MACCOLL et al. 2001. Interrelationships among biological activity, disulfide... Biochimica et Biophyscia Acta 1528: 127-134.	
		MORINAGA T. et al. 1983. Primary structures of human alpha fetoprotein.. Proc. Natl. Acad. Sci USA Vol 80 pp. 4604-4608	
		NAGATA S. 1997. Apoptosis by Death Factor. Cell 88:355-365	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(Use as many sheets as necessary)</i>		Complete if Known	
		Application Number	
		Filing Date	
		First Named Inventor	Dudich Elena
		Art Unit	
		Examiner Name	
Sheet		of	
		Attorney Docket Number	Caspase

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		Pasqualini, R. et al. 1995. A peptide isolated from phage display ... The Journal of Cell Biology. Vol 130: 5 pp. 1189-1196	

Examiner Signature	Date Considered	
-------------------------------	----------------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.